8380p 58.0 0.7%
Last Trade - 1:44pm
| Market Cap | £109.25bn |
| Enterprise Value | £118.12bn |
| Revenue | £19.76bn |
| Position in Universe | 10th / 1810 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 24,708 | 23,002 | 22,465 | 22,090 | 24,384 | 26,617 | 31,808 | 37,573 | +1.5% | ||
| +0.5 | -39.2 | -45.7 | -37.6 | +73.9 | +27.1 | +171.6 | +26.6 | |||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
AstraZeneca PLC is a biopharmaceutical company. It focuses on discovery and development of products, which are then manufactured, marketed and sold. It focuses on three main therapy areas: Oncology, Cardiovascular, Renal & Metabolic (CVRM) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVRM, it is expanding its portfolio into the cardiovascular-renal area with roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). It has approximately 38 projects in Phase I, including 26 new molecular entities (NMEs), and 12 oncology combination projects. It has approximately 43 projects in Phase II, including 25 NMEs; six additional indications for projects that have reached phase II, and 12 oncology combination projects. It has approximately 22 projects in late-stage development, either in Phase III/pivotal Phase II studies or under regulatory review.
| Last Annual | December 31st, 2020 |
| Last Interim | March 31st, 2021 |
| Incorporated | June 17, 1992 |
| Public Since | September 21, 2007 |
| No. of Shareholders: | 76,919 |
| No. of Employees: | 76,100 |
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Index | FTSE4GD UK 50, FTSE All Share , FTSE All-share - Health Care Price Return Gbp End Of Day, FTSE All-share - Pharmaceuticals & Biotechnology Price Return Gbp End Of Day, FTSEurofirst 300 Pharmaceuticals & Biotechnology , FTSEurofirst 100 , FTSEurofirst 300 , FTSEurofirst 300 Ex Eurozone, FTSE 350 Higher Yield , FTSE 350 , FTSE Global 100, FTSE 350 Pharmaceuticals & Biotechnology , FTSE 100 , FTSE Techmark All Share , , , |
| Exchange | London Stock Exchange (Full) |
| Shares in Issue | 1,312,772,156 |
| Free Float | (0.0%) |
| Eligible for |
✓
ISAs
✓
SIPPs
|
| Address | 1 Francis Crick Avenue, CAMBRIDGE, CB2 0AA, United Kingdom |
| Web | https://www.astrazeneca.com/Home |
| Phone | +44 20 73045000 |
| Contact | Thomas Larsen (Investor Relations) |
| Auditors | PricewaterhouseCoopers LLP |
As of 1:44pm, shares in AstraZeneca are trading at 8380p, giving the company a market capitalisation of £109.25bn. This share price information is delayed by 15 minutes.
Shares in AstraZeneca are currently trading at 8380p and the price has moved by -2.38% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the AstraZeneca price has moved by -18.16% over the past year.
Of the analysts with advisory recommendations for AstraZeneca, there are there are currently 10 "buy" , 1 "hold" and 1 "sell" recommendations. The overall consensus recommendation for AstraZeneca is Buy. You can view the full broker recommendation list by unlocking its StockReport.
AstraZeneca is scheduled to issue upcoming financial results on the following dates:
The AstraZeneca dividend yield is 2.36% based on the trailing twelve month period.
Last year, AstraZeneca paid a total dividend of 2.74, and it currently has a trailing dividend yield of 2.36%. Looking ahead, AstraZeneca has not announced an ex-dividend date yet.
AstraZeneca has yet to annouce their ex-dividend date. The historic dividend yield on AstraZeneca shares is currently 2.36%.
To buy shares in AstraZeneca you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in AstraZeneca are currently trading at 8380p, giving the company a market capitalisation of £109.25bn.
Here are the trading details for AstraZeneca:
Based on an overall assessment of its quality, value and momentum, AstraZeneca is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in AstraZeneca are currently priced at 8380p. At that level they are trading at 7.23% discount to the analyst consensus target price of 9,033.09.
Analysts covering AstraZeneca currently have a consensus Earnings Per Share (EPS) forecast of 5.127 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like AstraZeneca. Over the past six months, the relative strength of its shares against the market has been 6.79%. At the current price of 8380p, shares in AstraZeneca are trading at 6.87% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The AstraZeneca PE ratio based on its reported earnings over the past 12 months is 62.41. The shares are currently trading at 8380p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
AstraZeneca's management team is headed by:
Here are the top five shareholders of AstraZeneca based on the size of their shareholding:
